Determination of FCE 23884, a new ergolene derivative, and its possible metabolite, the 6-nor-derivative in plasma by high-performance liquid chromatography with fluorescence detection

A sensitive and selective high-performance liquid chromatographic method for the determination of FCE 23884 and its 6-nor-derivative (FCE 26506) in plasma has been developed. After buffering the plasma samples, the compounds and the internal standard were extracted with ethyl ether- n-octanol (9:1,...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 1993-04, Vol.11 (4), p.393-399
Main Authors: Marrari, P., Basileo, G., Pianezzola, E., Benedetti, M.Strolin
Format: Article
Language:English
Subjects:
Analysis
Biological and medical sciences
Chromatography, High Pressure Liquid
Dopamine Agents - blood
dopamine agonists
Ergolines - blood
fluorimetric detection
General pharmacology
Humans
Medical sciences
Pharmacology. Drug treatments
plasma drug levels
Quality Control
Reversed-phase high-performance liquid chromatography
Spectrometry, Fluorescence
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A sensitive and selective high-performance liquid chromatographic method for the determination of FCE 23884 and its 6-nor-derivative (FCE 26506) in plasma has been developed. After buffering the plasma samples, the compounds and the internal standard were extracted with ethyl ether- n-octanol (9:1, v/v), back-extracted into 0.01 M phosphoric acid and then analysed by reversed-phase liquid chromatography. Quantification was achieved by fluorescence detection of the eluate. The linearity, precision and accuracy of the method were evaluated. No interference from the biological matrix was observed. The assay was adequate for the quantification of plasma levels of the two compounds after a single oral dose of 1 mg of FCE 23884 in humans.
ISSN:0731-7085
1873-264X
DOI:10.1016/0731-7085(93)80035-Y